GSK is expanding its pipeline with two strategic external deals: a $950 million cash acquisition of Canadian 35Pharma to obtain HS235, a protein therapeutic for pulmonary hypertension, and an oligonucleotide pact that pays $40 million upfront to Frontier Biotechnologies with up to ~$1 billion in milestones. The 35Pharma buy brings a phase‑ready activin receptor pathway candidate, while the Frontier deal adds siRNA capabilities and accelerates GSK’s RNA strategy. Together the transactions illustrate GSK’s near‑term inorganic push across pulmonary and nucleic‑acid modalities.